The Symptomatic Cerebral Cavernous Malformation Trial of REC-994
This is a two-part, multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, efficacy and pharmacokinetics of REC-994 (200 mg and 400 mg) compared to placebo in subjects with symptomatic cerebral cavernous malformation (CCM).
Cerebral Cavernous Malformation
DRUG: REC-994|DRUG: Placebo
Incidence and severity of adverse events (AEs), Safety and tolerability, 24 months|Incidence of clinically significant changes in physical examinations, Safety and tolerability, 12 months (Part 2)
Change in patient reported outcomes (Cerebral Cavernous Malformation Health Index), Efficacy, 24 months|Change in patient reported outcomes (Modified Rankin Scale), Efficacy, 24 months|Change in patient reported outcomes (SymptoMScreen Score), Efficacy, 24 months|Change in disease-associated symptoms (size and number of lesions on MRI), Efficacy, 24 months|Change in disease-associated symptoms (number of MRI-confirmed cerebral hemorrhagic events), Efficacy, 24 months|Incidence of clinically significant changes in physical examinations, Safety and tolerability, 12 months (Part 1)
This is a two-part, multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, efficacy and pharmacokinetics of REC-994 (200 mg and 400 mg) compared to placebo in subjects with symptomatic cerebral cavernous malformation (CCM).